CD133 Stimulates Cell Proliferation via the Upregulation of Amphiregulin in Melanoma
Authors:
- Cynthia M Simbulan-RosenthalCynthia M Simbulan-Rosenthal
- Nusrat IslamNINusrat Islam
- Yogameenakshi HaribabuYHYogameenakshi Haribabu
- Ryyan AlobaidiRARyyan Alobaidi
- Azadeh ShalamzariASAzadeh Shalamzari
- Garrett GrahamGGGarrett Graham
- Li-Wei KuoLKLi-Wei Kuo
- Peter SykoraPSPeter Sykora
- Dean S RosenthalDean S Rosenthal
Open Access
Abstract
CD133, a cancer stem cell (CSC) marker in tumors, including melanoma, is associated with tumor recurrence, chemoresistance, and metastasis. Patient-derived melanoma cell lines were transduced with a Tet-on vector expressing CD133, generating doxycycline (Dox)-inducible cell lines. Cells were exposed to Dox for 24 h to induce CD133 expression, followed by RNA-seq and bioinformatic analyses, revealing genes and pathways that are significantly up- or downregulated by CD133. The most significantly upregulated gene after CD133 was amphiregulin (AREG), validated by qRT-PCR and immunoblot analyses. Induced CD133 expression significantly increased cell growth, percentage of cells in S-phase, BrdU incorporation into nascent DNA, and PCNA levels, indicating that CD133 stimulates cell proliferation. CD133 induction also activated EGFR and the MAPK pathway. Potential mechanisms highlighting the role(s) of CD133 and AREG in melanoma CSC were further delineated using AREG/EGFR inhibitors or siRNA knockdown of AREG mRNA. Treatment with the EGFR inhibitor gefitinib blocked CD133-induced cell growth increase and MAPK pathway activation. Importantly, siRNA knockdown of AREG reversed the stimulatory effects of CD133 on cell growth, indicating that AREG mediates the effects of CD133 on cell proliferation, thus serving as an attractive target for novel combinatorial therapeutics in melanoma and cancers with overexpression of both CD133 and AREG.Keywords
Funding Information
- NIEHS (5 R42 ES026908 03, 1R41ES032435-01, 5R42ES032435-03, 1R43GM139439)
- NIGMS (5 R42 ES026908 03, 1R41ES032435-01, 5R42ES032435-03, 1R43GM139439)
This publication has 61 references indexed in Scilit:
- Nuclear AREG affects a low‐proliferative phenotype and contributes to drug resistance of melanomaInternational Journal of Cancer, 2022
- Global Burden of Cutaneous Melanoma in 2020 and Projections to 2040JAMA Dermatology, 2022
- Epidermal growth factor receptor blockers for the treatment of ovarian cancerCochrane Database of Systematic Reviews, 2018
- Impact of insulin-like growth factor-1 receptor and amphiregulin expression on survival in patients with stage II/III gastric cancer enrolled in the Adjuvant Chemotherapy Trial of S-1 for Gastric CancerGastric Cancer, 2016
- Selecting the optimal Tet‐On system for doxycycline‐inducible gene expression in transiently transfected and stably transduced mammalian cellsBiotechnology Journal, 2015
- Amphiregulin confers trastuzumab resistance via AKT and ERK activation in HER2-positive breast cancerJournal of Cancer Research and Clinical Oncology, 2015
- CD133 Is Essential for Glioblastoma Stem Cell MaintenanceStem Cells, 2013
- NRAS mutation status is an independent prognostic factor in metastatic melanomaCancer, 2011
- The multiple roles of amphiregulin in human cancerBiochimica et Biophysica Acta (BBA) - Reviews on Cancer, 2011
- Knock‐down of amphiregulin inhibits cellular invasion in inflammatory breast cancerJournal of Cellular Physiology, 2011